{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:19:20Z","timestamp":1778660360484,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-281","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T13:11:42Z","timestamp":1398258702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis"],"prefix":"10.1186","volume":"14","author":[{"given":"Victoria","family":"Moneo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz G","family":"Serelde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Diaz-Uriarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C","family":"Tercero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amancio","family":"Carnero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"issue":"3","key":"4511_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","volume":"22","author":"S Popat","year":"2004","unstructured":"Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004, 22 (3): 529-536.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4511_CR2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1535-7163.MCT-05-0244","volume":"4","author":"P Seve","year":"2005","unstructured":"Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005, 4 (12): 2001-2007. 10.1158\/1535-7163.MCT-05-0244.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4511_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 2005, 205 (2): 275-292. 10.1002\/path.1706.","journal-title":"J Pathol"},{"issue":"10","key":"4511_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","volume":"9","author":"H Linardou","year":"2008","unstructured":"Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9 (10): 962-972. 10.1016\/S1470-2045(08)70206-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4511_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bcp.2009.04.003","volume":"78","author":"JF Leal","year":"2009","unstructured":"Leal JF, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garc\u00eda-Fern\u00e1ndez LF, Galmarini CM: Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol. 2009, 78 (2): 162-170. 10.1016\/j.bcp.2009.04.003.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4511_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3324\/haematol.2010.036400","volume":"96","author":"E Colado","year":"2011","unstructured":"Colado E, Paino T, Maiso P, Ocio EM, Chen X, Alvarez-Fernandez S, Gutierrez NC, Martin-Sanchez J, Flores-Montero J, San Segundo L, Garayoa M, Fern\u00e1ndez-L\u00e1zaro D, Vidriales MB, Galmarini CM, Avil\u00e9s P, Cuevas C, Pandiella A, San-Miguel JF: Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011, 96 (5): 687-695. 10.3324\/haematol.2010.036400.","journal-title":"Haematologica"},{"issue":"7","key":"4511_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1158\/1535-7163.MCT-09-0336","volume":"8","author":"J Guirouilh-Barbat","year":"2009","unstructured":"Guirouilh-Barbat J, Antony S, Pommier Y: Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther. 2009, 8 (7): 2007-2014. 10.1158\/1535-7163.MCT-09-0336.","journal-title":"Mol Cancer Ther"},{"issue":"41","key":"4511_CR8","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1021\/bi960306b","volume":"35","author":"Y Pommier","year":"1996","unstructured":"Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996, 35 (41): 13303-13309. 10.1021\/bi960306b.","journal-title":"Biochemistry"},{"issue":"16","key":"4511_CR9","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","volume":"66","author":"AB Herrero","year":"2006","unstructured":"Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006, 66 (16): 8155-8162. 10.1158\/0008-5472.CAN-06-0179.","journal-title":"Cancer Res"},{"issue":"8","key":"4511_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/91008","volume":"7","author":"Y Takebayashi","year":"2001","unstructured":"Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001, 7 (8): 961-966. 10.1038\/91008.","journal-title":"Nat Med"},{"issue":"11\u201312","key":"4511_CR11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3727\/0965040042707925","volume":"14","author":"E Erba","year":"2004","unstructured":"Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, Riccardi R, Cuevas C, Faircloth GT, D\u2019Incalci M: The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res. 2004, 14 (11\u201312): 579-587.","journal-title":"Oncol Res"},{"issue":"6","key":"4511_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00280-008-0843-2","volume":"63","author":"Z Duan","year":"2009","unstructured":"Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol. 2009, 63 (6): 1121-1129. 10.1007\/s00280-008-0843-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"4511_CR13","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1182\/blood-2008-09-177774","volume":"113","author":"EM Ocio","year":"2009","unstructured":"Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Avil\u00e9s P, Cuevas C, San-Miguel JF, Pandiella A: Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood. 2009, 113 (16): 3781-3791. 10.1182\/blood-2008-09-177774.","journal-title":"Blood"},{"issue":"2","key":"4511_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.21073","volume":"100","author":"V Moneo","year":"2007","unstructured":"Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sanchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A: Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007, 100 (2): 339-348. 10.1002\/jcb.21073.","journal-title":"J Cell Biochem"},{"issue":"5","key":"4511_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00148581-200810050-00005","volume":"10","author":"AJ Chou","year":"2008","unstructured":"Chou AJ, Geller DS, Gorlick R: Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs. 2008, 10 (5): 315-327. 10.2165\/00148581-200810050-00005.","journal-title":"Paediatr Drugs"},{"issue":"14","key":"4511_CR16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/sj.onc.1210846","volume":"27","author":"JF Leal","year":"2008","unstructured":"Leal JF, Fominaya J, Cascon A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon YCS, Robledo M, Beach DH, Carnero A: Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 2008, 27 (14): 1961-1970. 10.1038\/sj.onc.1210846.","journal-title":"Oncogene"},{"issue":"4","key":"4511_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1535-7163.MCT-06-0729","volume":"6","author":"V Moneo","year":"2007","unstructured":"Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A: Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther. 2007, 6 (4): 1310-1316. 10.1158\/1535-7163.MCT-06-0729.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"4511_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1373\/clinchem.2010.147686","volume":"56","author":"SR Master","year":"2010","unstructured":"Master SR: Getting the details right: gene signatures for cancer therapy. Clin Chem. 2010, 56 (9): 1378-1380. 10.1373\/clinchem.2010.147686.","journal-title":"Clin Chem"},{"issue":"7074","key":"4511_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature04296","volume":"439","author":"AH Bild","year":"2006","unstructured":"Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439 (7074): 353-357. 10.1038\/nature04296.","journal-title":"Nature"},{"issue":"3","key":"4511_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/156800908784293659","volume":"8","author":"A Carnero","year":"2008","unstructured":"Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF: The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008, 8 (3): 187-198. 10.2174\/156800908784293659.","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"4511_CR21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/01.cad.0000180117.93535.cf","volume":"16","author":"C Blanco-Aparicio","year":"2005","unstructured":"Blanco-Aparicio C, Pequeno B, Moneo V, Romero L, Leal JF, Velasco J, Fominaya J, Carnero A: Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs. 2005, 16 (9): 977-987. 10.1097\/01.cad.0000180117.93535.cf.","journal-title":"Anticancer Drugs"},{"issue":"20","key":"4511_CR22","doi-asserted-by":"publisher","first-page":"21085","DOI":"10.1074\/jbc.M400063200","volume":"279","author":"SJ Gardai","year":"2004","unstructured":"Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL, Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 2004, 279 (20): 21085-21095. 10.1074\/jbc.M400063200.","journal-title":"J Biol Chem"},{"issue":"53","key":"4511_CR23","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.1038\/sj.onc.1204984","volume":"20","author":"H Yamaguchi","year":"2001","unstructured":"Yamaguchi H, Wang HG: The protein kinase PKB\/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 2001, 20 (53): 7779-7786. 10.1038\/sj.onc.1204984.","journal-title":"Oncogene"},{"issue":"5","key":"4511_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/jcb.20479","volume":"95","author":"W Link","year":"2005","unstructured":"Link W, Rosado A, Fominaya J, Thomas JE, Carnero A: Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem. 2005, 95 (5): 979-989. 10.1002\/jcb.20479.","journal-title":"J Cell Biochem"},{"issue":"2","key":"4511_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/156800910791054158","volume":"10","author":"F Zanella","year":"2010","unstructured":"Zanella F, Link W, Carnero A: Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets. 2010, 10 (2): 135-146. 10.2174\/156800910791054158.","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"4511_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/sj.onc.1205181","volume":"21","author":"TM Gottlieb","year":"2002","unstructured":"Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M: Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002, 21 (8): 1299-1303. 10.1038\/sj.onc.1205181.","journal-title":"Oncogene"},{"issue":"56","key":"4511_CR27","doi-asserted-by":"publisher","first-page":"8999","DOI":"10.1038\/sj.onc.1207111","volume":"22","author":"AD Cox","year":"2003","unstructured":"Cox AD, Der CJ: The dark side of Ras: regulation of apoptosis. Oncogene. 2003, 22 (56): 8999-9006. 10.1038\/sj.onc.1207111.","journal-title":"Oncogene"},{"key":"4511_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0076-6879(01)33046-X","volume":"333","author":"MW Mayo","year":"2001","unstructured":"Mayo MW, Norris JL, Baldwin AS: Ras regulation of NF-kappa B and apoptosis. Methods Enzymol. 2001, 333: 73-87.","journal-title":"Methods Enzymol"},{"issue":"Suppl 1","key":"4511_CR29","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1677\/erc.1.01275","volume":"13","author":"HE Jones","year":"2006","unstructured":"Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI: Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006, 13 (Suppl 1): S45-S51.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4511_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1517\/14712590902735795","volume":"13","author":"EA Hopper-Borge","year":"2009","unstructured":"Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I: Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009, 13 (3): 339-362. 10.1517\/14712590902735795.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"4511_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4161\/cbt.23627","volume":"14","author":"G Hrustanovic","year":"2013","unstructured":"Hrustanovic G, Lee BJ, Bivona TG: Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013, 14 (4): 304-314. 10.4161\/cbt.23627.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"4511_CR32","first-page":"181","volume":"10","author":"DJ Beech","year":"2003","unstructured":"Beech DJ, Perer E, Helms J, Gratzer A, Deng N: Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep. 2003, 10 (1): 181-184.","journal-title":"Oncol Rep"},{"issue":"10","key":"4511_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/00001813-200511000-00009","volume":"16","author":"AH Braun","year":"2005","unstructured":"Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U: The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs. 2005, 16 (10): 1099-1108. 10.1097\/00001813-200511000-00009.","journal-title":"Anticancer Drugs"},{"issue":"20","key":"4511_CR34","doi-asserted-by":"publisher","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-08-0821","volume":"14","author":"M Michaelis","year":"2008","unstructured":"Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J: Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res. 2008, 14 (20): 6531-6537. 10.1158\/1078-0432.CCR-08-0821.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"4511_CR35","first-page":"6756","volume":"62","author":"J Jaboin","year":"2002","unstructured":"Jaboin J, Kim CJ, Kaplan DR, Thiele CJ: Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3\u2032-kinase pathway. Cancer Res. 2002, 62 (22): 6756-6763.","journal-title":"Cancer Res"},{"issue":"8","key":"4511_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bcp.2006.07.022","volume":"72","author":"HM Coley","year":"2006","unstructured":"Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H: Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006, 72 (8): 941-948. 10.1016\/j.bcp.2006.07.022.","journal-title":"Biochem Pharmacol"},{"issue":"4\u20136","key":"4511_CR37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000086998","volume":"68","author":"CH Hsu","year":"2005","unstructured":"Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL: Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology. 2005, 68 (4\u20136): 538-547.","journal-title":"Oncology"},{"issue":"7","key":"4511_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0898-6568(01)00173-5","volume":"13","author":"RR Mattingly","year":"2001","unstructured":"Mattingly RR, Milstein ML, Mirkin BL: Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. Cell Signal. 2001, 13 (7): 499-505. 10.1016\/S0898-6568(01)00173-5.","journal-title":"Cell Signal"},{"issue":"5","key":"4511_CR39","first-page":"1691","volume":"40","author":"A Takeuchi","year":"2012","unstructured":"Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S: Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1\/2 phosphorylation. Int J Oncol. 2012, 40 (5): 1691-1696.","journal-title":"Int J Oncol"},{"key":"4511_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/1471-2407-12-514","volume":"12","author":"P Estevez-Garcia","year":"2012","unstructured":"Estevez-Garcia P, Castano A, Martin AC, Lopez-Rios F, Iglesias J, Munoz-Galvan S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R: PDGFRalpha\/beta and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer. 2012, 12: 514-10.1186\/1471-2407-12-514.","journal-title":"BMC Cancer"},{"issue":"8","key":"4511_CR41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009, 35 (8): 692-706. 10.1016\/j.ctrv.2009.08.004.","journal-title":"Cancer Treat Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-281\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:47:46Z","timestamp":1630554466000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4511"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-281","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,23]]},"assertion":[{"value":"9 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"281"}}